Go Pro

Johnson & Johnson (JNJ) Stock Price, News & Analysis

Johnson & Johnson logo
$256.96 +2.03 (+0.80%)
As of 10:28 AM Eastern

About Johnson & Johnson Stock (NYSE:JNJ)

Advanced

Key Stats

Today's Range
$254.47
$257.64
50-Day Range
$223.00
$267.35
52-Week Range
$169.68
$274.90
Volume
940,723 shs
Average Volume
8.37 million shs
Market Capitalization
$619.25 billion
P/E Ratio
29.78
Dividend Yield
2.09%
Price Target
$267.48
Consensus Rating
Moderate Buy

Company Overview

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience. Its medical devices segment supplies surgical products, orthopedics and interventional solutions through well-known businesses including Ethicon and DePuy Synthes, serving hospitals, physicians and health systems with products for surgery, joint reconstruction and cardiovascular care.

Historically, Johnson & Johnson was also a major consumer health products company with brands for over-the-counter medicines, skincare and first aid; many of those consumer health assets were separated into a standalone publicly traded company, Kenvue, in 2023. J&J continues to emphasize innovation and research, investing in drug discovery, clinical development and device technology while collaborating with academic and industry partners to bring new therapies and technologies to market.

Management is led by Chief Executive Officer Joaquin Duato, who assumed the role in early 2022. The company’s global footprint, diversified portfolio and sizable research infrastructure position it as a prominent participant in the healthcare sector, serving patients, clinicians and consumers across multiple geographies and care settings.

AI Generated. May Contain Errors.

Johnson & Johnson Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

JNJ MarketRank™: 

Johnson & Johnson scored higher than 93% of companies evaluated by MarketBeat, and ranked 33rd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Johnson & Johnson has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 18 buy ratings, 6 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for Johnson & Johnson is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Johnson & Johnson has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Johnson & Johnson's stock forecast and price target.
  • Earnings Growth

    Earnings for Johnson & Johnson are expected to grow by 9.58% in the coming year, from $11.69 to $12.81 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Johnson & Johnson is 29.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.41.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Johnson & Johnson is 29.58, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 279.15.

  • Price to Earnings Growth Ratio

    Johnson & Johnson has a PEG Ratio of 2.41. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Johnson & Johnson has a P/B Ratio of 7.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Johnson & Johnson's valuation and earnings.
  • Percentage of Shares Shorted

    1.14% of the float of Johnson & Johnson has been sold short.
  • Short Interest Ratio / Days to Cover

    Johnson & Johnson has a short interest ratio ("days to cover") of 3.67, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Johnson & Johnson has recently increased by 3.19%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Johnson & Johnson pays a meaningful dividend of 2.11%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Johnson & Johnson has been increasing its dividend for 64 years.

  • Dividend Coverage

    The dividend payout ratio of Johnson & Johnson is 62.11%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 41.84% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.

  • Read more about Johnson & Johnson's dividend.
  • News Sentiment

    Johnson & Johnson has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 89 news articles for Johnson & Johnson this week, compared to 11 articles on an average week.
  • Search Interest

    180 people have searched for JNJ on MarketBeat in the last 30 days. This is an increase of 54% compared to the previous 30 days.
  • MarketBeat Follows

    89 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is an increase of 170% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Johnson & Johnson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,204,279.00 in company stock.

  • Percentage Held by Insiders

    0.16% of the stock of Johnson & Johnson is held by insiders.

  • Percentage Held by Institutions

    69.55% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Johnson & Johnson's insider trading history.
Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JNJ Stock News Headlines

Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
BAYRY Beats on Q2 Earnings, Crop Science Business Boosts Growth
Laptop displaying stock price and bar charts on a desk, surrounded by icons representing tech, banking, healthcare, and retail sectors.
The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure (JNJ)
As the NASDAQ-100 corrects amid an AI CapEx-driven tech sell-off, sectors like healthcare and financials are rallying, boosting diversified value ETFs like the Schwab U.S. Large-Cap Value ETF (SCHV).
Illustration of two trees, one with gold coin leaves and one with green leaves and hanging dollar coins, symbolizing investment growth.
This Dividend ETF Choice Could Shape Your Income Strategy Through 2026 (JNJ)
VYM and SCHD both offer low-cost dividend exposure, but differ in methodology, yield, and holdings—VYM emphasizes broad, higher-yield diversification, while SCHD focuses on stricter, dividend-growth criteria.
Laptop displaying financial dashboard with charts on a desk, set against a background of rising stock candlestick charts.
5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama (JNJ)
While AI stocks correct, Johnson & Johnson, Altria, Coca-Cola, JPMorgan, and Apple are quietly trading near 52-week or all-time highs ahead of earnings.
A home office desk with a laptop displaying a Daily Market Pulse financial report, beside a coffee mug and notebook.
MarketBeat Week in Review – 07/13- 07/17 (JNJ)
A tech selloff hit the S&P 500 and NASDAQ this week while energy and financial stocks gained; MarketBeat analysts recap Micron, Netflix, Broadcom, Apple and more ahead of Alphabet's earnings.
See More Headlines

JNJ Stock Analysis - Frequently Asked Questions

Johnson & Johnson's stock was trading at $207.07 at the start of the year. Since then, JNJ stock has increased by 23.3% and is now trading at $255.26.

Johnson & Johnson (NYSE:JNJ) released its earnings results on Wednesday, July, 15th. The company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.06. The company's revenue for the quarter was up 6.6% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of Johnson & Johnson: Momenta Pharmaceuticals, TARIS Biomedical, Verb Surgical, Auris Health, Ci:z Holdings, Zarbee's Naturals, Orthotaxy, and others.

Johnson & Johnson's top institutional shareholders include Massachusetts Financial Services Co. MA (0.44%), TD Asset Management Inc (0.20%), Principal Financial Group Inc. (0.14%) and Handelsbanken Fonder AB (0.08%). Insiders that own company stock include & Johnson Johnson, Jennifer L Taubert, Kathryn E Wengel, Timothy Schmid, Vanessa Broadhurst, Robert J Decker and Mark A Weinberger.
View institutional ownership trends
.

Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Johnson & Johnson investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), UnitedHealth Group (UNH), Gilead Sciences (GILD), Corning (GLW), NextEra Energy (NEE) and Devon Energy (DVN).

Company Calendar

Record date for 6/9 Dividend
5/26/2026
Ex-Dividend for 6/9 Dividend
5/26/2026
Dividend Payable
6/09/2026
Last Earnings
7/15/2026
Today
8/05/2026
Record date for 9/8 Dividend
8/25/2026
Ex-Dividend for 9/8 Dividend
8/25/2026
Dividend Payable
9/08/2026
Wells Fargo 21st Annual Healthcare Conference
9/09/2026
Next Earnings (Estimated)
10/13/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:JNJ
CIK
200406
Employees
138,200
Year Founded
1886

Price Target and Rating

High Price Target
$305.00
Low Price Target
$210.00
Potential Upside/Downside
+4.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
25 Analysts

Profitability

EPS (Trailing Twelve Months)
$8.63
Trailing P/E Ratio
29.80
Forward P/E Ratio
22.00
P/E Growth
2.41
Net Income
$26.80 billion
Net Margins
21.48%
Pretax Margin
25.73%
Return on Equity
32.42%
Return on Assets
13.35%

Debt

Debt-to-Equity Ratio
0.44
Current Ratio
1.09
Quick Ratio
0.81

Sales & Book Value

Annual Sales
$94.19 billion
Price / Sales
6.58
Cash Flow
$14.27 per share
Price / Cash Flow
18.02
Book Value
$35.26 per share
Price / Book
7.29

Miscellaneous

Outstanding Shares
2,409,900,000
Free Float
2,406,042,000
Market Cap
$619.80 billion
Optionable
Optionable
Beta
0.24

Social Links

The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NYSE:JNJ) was last updated on 8/5/2026 by MarketBeat.com Staff.
From Our Partners